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Opioid agonist treatment for pharmaceutical opioid dependent people (Review) 
Abstract 
Background There are increasing concerns regarding pharmaceutical opioid harms including overdose 
and dependence, with an associated increase in treatment demand. People dependent on pharmaceutical 
opioids appear to differ in important ways from people who use heroin, yet most opioid agonist treatment 
research has been conducted in people who use heroin. Objectives To assess the effects of maintenance 
agonist pharmacotherapy for the treatment of pharmaceutical opioid dependence. Search methods The 
search included the Cochrane Drugs and Alcohol Group's Specialised Register of Trials; the Cochrane 
Central Register of Controlled Trials (CENTRAL, 2015, Issue 5); PubMed (January 1966 to May 2015); 
EMBASE (Ovid) (January 1974 to May 2015); CINAHL (EBSCOhost) (1982 to May 2015); ISI Web of 
Science (to May 2014); and PsycINFO (Ovid) (1806 to May 2014). Selection criteria We included 
randomised controlled trials examining maintenance opioid agonist treatments that made the following 
two comparisons: 1. full opioid agonists (methadone, morphine, oxycodone, levo‐alpha‐acetylmethadol 
(LAAM), or codeine) versus different full opioid agonists or partial opioid agonists (buprenorphine) for 
maintenance treatment and 2. full or partial opioid agonist maintenance versus placebo, detoxification 
only, or psychological treatment (without opioid agonist treatment). Data collection and analysis We used 
standard Cochrane methodological procedures. Main results We identified six randomised controlled 
trials that met inclusion criteria (607 participants). We found moderate quality evidence from two studies 
of no difference between methadone and buprenorphine in self reported opioid use (risk ratio (RR) 0.37, 
95% confidence interval (CI) 0.08 to 1.63) or opioid positive urine drug tests (RR 0.81, 95% CI 0.56 to 
1.18). There was low quality evidence from three studies of no difference in retention between 
buprenorphine and methadone maintenance treatment (RR 0.69, 95% CI 0.39 to 1.22). There was 
moderate quality evidence from two studies of no difference between methadone and buprenorphine on 
adverse events (RR 1.10, 95% CI 0.64 to 1.91). We found low quality evidence from three studies favouring 
maintenance buprenorphine treatment over detoxification or psychological treatment in terms of fewer 
opioid positive urine drug tests (RR 0.63, 95% CI 0.43 to 0.91) and self reported opioid use in the past 30 
days (RR 0.54, 95% CI 0.31 to 0.93). There was no difference on days of unsanctioned opioid use 
(standardised mean difference (SMD) ‐0.31, 95% CI ‐0.66 to 0.04). There was moderate quality evidence 
favouring buprenorphine maintenance over detoxification or psychological treatment on retention in 
treatment (RR 0.33, 95% CI 0.23 to 0.47). There was moderate quality evidence favouring buprenorphine 
maintenance over detoxification or psychological treatment on adverse events (RR 0.19, 95% CI 0.06 to 
0.57). The main weaknesses in the quality of the data was the use of open‐label study designs. Authors' 
conclusions There was low to moderate quality evidence supporting the use of maintenance agonist 
pharmacotherapy for pharmaceutical opioid dependence. Methadone or buprenorphine appeared equally 
effective. Maintenance treatment with buprenorphine appeared more effective than detoxification or 
psychological treatments. Due to the overall low to moderate quality of the evidence and small sample 
sizes, there is the possibility that the further research may change these findings. 
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A B S T R A C T
Background
There are increasing concerns regarding pharmaceutical opioid harms including overdose and dependence, with an associated increase
in treatment demand. People dependent on pharmaceutical opioids appear to differ in important ways from people who use heroin,
yet most opioid agonist treatment research has been conducted in people who use heroin.
Objectives
To assess the effects of maintenance agonist pharmacotherapy for the treatment of pharmaceutical opioid dependence.
Search methods
The search included the Cochrane Drugs and Alcohol Group’s Specialised Register of Trials; the Cochrane Central Register of Controlled
Trials (CENTRAL, 2015, Issue 5); PubMed (January 1966 to May 2015); EMBASE (Ovid) (January 1974 to May 2015); CINAHL
(EBSCOhost) (1982 to May 2015); ISI Web of Science (to May 2014); and PsycINFO (Ovid) (1806 to May 2014).
Selection criteria
We included randomised controlled trials examining maintenance opioid agonist treatments that made the following two comparisons:
1. full opioid agonists (methadone, morphine, oxycodone, levo-alpha-acetylmethadol (LAAM), or codeine) versus different full opioid
agonists or partial opioid agonists (buprenorphine) for maintenance treatment and
2. full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment (without opioid agonist
treatment).
Data collection and analysis
We used standard Cochrane methodological procedures.
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Main results
We identified six randomised controlled trials that met inclusion criteria (607 participants).
We found moderate quality evidence from two studies of no difference between methadone and buprenorphine in self reported opioid
use (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.08 to 1.63) or opioid positive urine drug tests (RR 0.81, 95% CI 0.56 to 1.18).
There was low quality evidence from three studies of no difference in retention between buprenorphine and methadone maintenance
treatment (RR 0.69, 95% CI 0.39 to 1.22). There was moderate quality evidence from two studies of no difference between methadone
and buprenorphine on adverse events (RR 1.10, 95% CI 0.64 to 1.91).
We found low quality evidence from three studies favouring maintenance buprenorphine treatment over detoxification or psychological
treatment in terms of fewer opioid positive urine drug tests (RR 0.63, 95% CI 0.43 to 0.91) and self reported opioid use in the past
30 days (RR 0.54, 95% CI 0.31 to 0.93). There was no difference on days of unsanctioned opioid use (standardised mean difference
(SMD) -0.31, 95% CI -0.66 to 0.04). There was moderate quality evidence favouring buprenorphine maintenance over detoxification
or psychological treatment on retention in treatment (RR 0.33, 95% CI 0.23 to 0.47). There was moderate quality evidence favouring
buprenorphine maintenance over detoxification or psychological treatment on adverse events (RR 0.19, 95% CI 0.06 to 0.57).
The main weaknesses in the quality of the data was the use of open-label study designs.
Authors’ conclusions
There was low to moderate quality evidence supporting the use of maintenance agonist pharmacotherapy for pharmaceutical opioid
dependence. Methadone or buprenorphine appeared equally effective. Maintenance treatment with buprenorphine appeared more
effective than detoxification or psychological treatments.
Due to the overall low to moderate quality of the evidence and small sample sizes, there is the possibility that the further research may
change these findings.
P L A I N L A N G U A G E S U M M A R Y
Opioid maintenance medicines for the treatment of dependence on opioid pain medicines
Background
Use of pharmaceutical opioids (medicines that are used to treat pain) has increased dramatically in some parts of the world since the
mid-1990s. With the increased use, there has been increasing numbers of people seeking treatment for dependence (addiction) on
pharmaceutical opioids. Currently, most treatment guidelines are based on research that was conducted in people who were dependent
on heroin (a highly addictive opioid). This review sought to compare different opioid agonist maintenance treatments (i.e. treatments
such as methadone or buprenorphine that are given for at least 30 days to help the person to reduce their unsanctioned drug use) for
the treatment of pharmaceutical opioid dependence. We also compared results from maintenance treatment to short term treatments
such as detoxification (removal of the drug from the body) or psychological treatments (e.g. talking therapy, counselling).
Study characteristics
We examined the scientific literature up to May 2015. We identified six randomised controlled trials (studies where people were allocated
at random to one of two or more treatment or control conditions) involving 607 people who were dependent on pharmaceutical opioids.
The people in the study were 77% male and had an average age of 31.6 years. The average duration of the studies comparing different
opioid maintenance treatments (three studies that compared methadone to buprenorphine) was 24 weeks, and the average duration
of studies comparing a maintenance treatment (three studies with buprenorphine maintenance) to detoxification or psychological
treatment was 10 weeks. Five of the six studies were conducted in the US, with one study from Iran.
We looked at opioid use and leaving treatment early.
Five of the studies were funded by the National Institute of Health (USA), with one study not reporting the funding source. Four
studies reported that a drug company provided the medicine.
Key results
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We found that there is probably little or no difference between how well methadone and buprenorphine worked to keep people in
treatment, to reduce opioid use, or side effects. We found that buprenorphine probably keeps more people in treatment, may reduce
use of opioids, and has fewer side effects compared to detoxification or psychological treatment alone.
Quality of the evidence
Overall, the evidence was of low to moderate quality. All studies put people into treatment groups randomly, but the participants and
researchers knew which medication the participants were taking, which could bias the results and lower the quality of the evidence.
Some of the studies had reasonable numbers of people who did not finish the study in both treatment groups, which means there are
some missing results, but the number of people with missing results was similar in both treatment groups of the study for most studies.
Most of the studies were similar in design and results were collected in a way that allowed them to compare opioid use and number of
people completing the study.
3Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Full opioid agonists versus different full opioid agonists or partial opioid agonists (methadone versus buprenorphine) for maintenance
Patient or population: pharmaceut ical opioid dependent people
Intervention: methadone
Comparison: buprenorphine
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436 per 1000 353 per 1000
(244 to 514)
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(31 to 623)
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631 per 1000 436 per 1000
(246 to 770)
-
382 per 1000 264 per 1000
(149 to 467)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 All studies were open label. In addit ion, one study presented lim ited information meaning that we were unable to assess risk
of bias
2 Signif icant heterogeneity, P value = 0.04; I2 = 68% when the meta-analyses included Ahmadi 2003. This is not apparent (12 =











































































































B A C K G R O U N D
Description of the condition
The non-medical use of, and dependence to, pharmaceutical drugs
has been described as a major health problem. An estimated 26
to 36 million people were using opioids in 2010, with around
half using pharmaceutical opioids (UNODC 2012). There are an
estimated 15.6 million opioid dependent people worldwide, with
the global consumption of opioids considered to be increasing (
WHO 2009). Opioid dependence is a chronic relapsing condition
with significant cost to human life (Hser 2001; Grella 2011).
Dependence on pharmaceutical opioids has been well established
as a problem in the US and Canada (Fischer 2012; Manchikanti
2012). In the USA, pharmaceutical opioids are increasingly used
by young people, and pain medications are second to marijuana
as the drug used by new illicit drug initiates (NSDUH 2011).
Globally, illicit opioid use is a major cause of mortality from both
acute effects of intoxication (e.g. overdose and traffic accidents)
and transmission of blood-borne disease associated with injection
drug use (such as human immunodeficiency virus (HIV) and hep-
atitis C) (Degenhardt 2011). In the USA, where pharmaceutical
opioid use has been described as an epidemic, pharmaceutical opi-
oid overdose is one of the leading cause of mortality, with deaths
from pharmaceutical opioids exceeding the number of deaths from
heroin and cocaine (Compton 2015). In the USA in 2007, more
people died from prescription opioid overdose than motor vehicle
accidents and suicides (Manchikanti 2012). A more recent trend
of declining mortality from prescription opioids was observed in
young people, while among older adults, mortality has contin-
ued to increase (West 2015). Similarly high rates of pharmaceuti-
cal opioid use have been described in Canada (Fischer 2012). Al-
though other countries are yet to reach the magnitude of the prob-
lems seen in the USA and Canada, there is evidence of increased
pharmaceutical opioid use and harms. One global review identi-
fied that pharmaceutical opioid diversion, non-medical use and in-
jection was a considerable problem in the USA, South Asia, South
East Asia, and some European countries (Degenhardt 2007). In
Europe, non-medical use of prescription opioids is documented,
including the problematic use of non-prescription codeine in the
UK and France. However, the risk of a prescription opioid epi-
demic on the scale of what was observed in North America is
thought to be low (van Amsterdam 2015). An estimated 1.6% to
1.7% of the German population are thought to be dependent on
prescription drugs (Casati 2012). Increasing treatment presenta-
tions with prescription and over-the-counter (non-prescription)
codeine opioids are reported in South Africa, where 5% to 8% of
treatment presentations are now associated with over-the-counter
opioid dependence (Weich 2008). Increasing reports of use and
harms with pharmaceutical opioids are also reported in Australia,
with increasing mortality due to oxycodone, and increasing hos-
pital presentations for pharmaceutical opioids including over-the-
counter codeine (Frei 2010; Rintoul 2010; Roxburgh 2011). The
number of hospital poisonings in Australia from pharmaceutical
opioids exceeded heroin in 2004 and has continued to grow every
year, and the number of treatment episodes are increasing, though
heroin dependence remains the main opioid people seek treatment
for (Roxburgh 2011; Nielsen 2015a).
Description of the intervention
Opioid agonist treatments are established to be effective in the
treatment of heroin dependence (Clark 2002; Faggiano 2003;
Mattick 2009; Mattick 2014). The two main opioid agonist treat-
ments that are most widely available are methadone and buprenor-
phine.
Methadone is well established as a treatment and has a strong
evidence base demonstrating its effectiveness in reducing mor-
tality and substance use, improving physical and mental health
outcomes, reducing criminal activity, and reducing HIV risk and
risk behaviours (Caplehorn 1996; Amato 2005; Gowing 2011;
Gowing 2012; Gowing 2013; Mattick 2014).
Methadone is a synthetic µ-opioid agonist, and an N-methyl-D-
aspartate (NMDA) antagonist. It has a half-life of 24 to 36 hours
and has close to 100% oral bioavailability. Methadone is generally
given as a single daily dose in the treatment of opioid dependence.
Methadone doses of 60 to 100 mg are more effective in retaining
people in treatment compared with lower doses (Faggiano 2003).
Buprenorphine is a partial opioid agonist, having a lower intrinsic
activity at the opioid receptor, but, due to its high affinity for the
opioid receptor, buprenorphine has antagonist actions, blocking
the effect of other opioids. Buprenorphine has a favourable safety
profile due to its ceiling on respiratory effects (Walsh 1994), with
mortality in treatment appearing to be relatively less common with
buprenorphine compared with methadone in naturalistic study
designs in Australia and France (Auriacombe 2001; Degenhardt
2009). Buprenorphine has poor oral bioavailability, and is available
in sublingual formulations for the treatment of opioid dependence.
Due to its pharmacological properties, buprenorphine is able to
be given as larger doses every second or third day (Amass 2000).
Levo-alpha-acetylmethadol (LAAM) was concluded to be more
effective than methadone for reducing heroin use (Clark 2002),
but it is currently not commercially available. Other therapies such
as slow release oral morphine have also been explored.
How the intervention might work
Opioid agonist treatment, also known as opioid maintenance
treatment, involves prescribing maintenance doses of an opioid
medication in place of the drug of dependence. Most of the origi-
nal research into opioid maintenance treatment involved prescrib-
ing a legal opioid such as methadone or buprenorphine to treat
illicit opioid (e.g. heroin) dependence. The provision of a regular
6Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
dose of a legal opioid treatment enables a reduction in illicit or
unsanctioned opioid use, with improvements in health and social
stability. The dose of the medication is adjusted to a level that re-
duces withdrawal and craving without causing excessive sedation.
Regular dosing maintains a fairly constant blood level, so that the
sense of euphoria or intoxication usually associated with each dose
of the drug (either illicit or prescribed) is lessened. Maintenance
treatment decreases the frequency and intensity of the cycle of in-
toxication and withdrawal, allowing the client to address the as-
sociated issues necessary for recovery better. Psychosocial support
provided in conjunction with medication can help to address the
psychological health and social problems that can be associated
with opioid use, and therefore help to improve quality of life and
prevent premature mortality (WHO 2009).
Opioid agonist treatment works by provision of a regular dose of
µ-opioid agonist that binds at the µ-opioid receptor, alleviating
opioid withdrawal symptoms. Providing a stable dose of opioid
agonist has been demonstrated to lead to numerous health and
social benefits for opioid dependent people, specifically though
reducing illicit opioid use (Amato 2005; Mattick 2009; Mattick
2014), HIV risk behaviour (Gowing 2011), HIV seroconversion
(MacArthur 2012), and criminality (Amato 2005; Mattick 2009).
It has been confirmed to improve physical and mental health, and
social functioning (Padaiga 2007; Mattick 2009; Mattick 2014),
and reduce mortality (Degenhardt 2011).
Why it is important to do this review
Opioid agonist treatment is commonly initiated as a first-line treat-
ment for people with pharmaceutical opioid dependence, even
though much of the evidence base for the use of pharmacotherapy
in opioid dependence has been derived from studies conducted
primarily or exclusively with heroin-dependent samples. People
who use pharmaceutical opioids (i.e. both prescription opioids and
over-the-counter opioids such as codeine) have been described in
the literature to be a patient population with a number of charac-
teristics that differ from heroin-using populations, including be-
ing more likely to be white, employed, less likely to use drugs by
injection, and having a higher prevalence of physical and mental
health co-morbidities (Brands 2004; Moore 2007; Fischer 2008;
Nielsen 2011; Nielsen 2015a). How these characteristics may im-
pact on treatment outcomes is not well understood. Further, stud-
ies that have compared treatment outcomes for people who use
pharmaceutical opioids and heroin have had mixed results, with
some studies finding better treatment outcomes for people us-
ing pharmaceutical opioids, and other studies finding no differ-
ence (Banta-Green 2009; McCabe 2013; Nielsen 2013; Nielsen
2015b).
Pharmaceutical opioid dependence is at epidemic levels in the
USA and is increasing globally. Establishing an evidence base for
treatment of prescription opioid dependence is therefore timely
and critical. An emerging evidence base exists for the use of opioid
agonist treatments in prescription opioid dependence, but a sys-
tematic review is yet to be conducted to determine whether sim-
ilar outcomes can be expected for this new population of opioid
dependent people. This review will fill an evidence gap informing
clinicians about effective approaches using agonist pharmacother-
apies for pharmaceutical opioid dependence.
O B J E C T I V E S
To assess the effects of maintenance agonist pharmacotherapy for
the treatment of pharmaceutical opioid dependence.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
We included studies with people who were assessed by study staff
to meet Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV), International Statistical Classification of
Diseases and Related Health Problems, 10th Revision (ICD-10),
or other validated criteria for pharmaceutical opioid dependence,
or were assessed by a clinician to meet criteria for pharmaceutical
opioid dependence (i.e. a population meeting criteria for ’addic-
tion’ rather than just physiological neuro-adaptation in the ab-
sence of other behaviours suggesting dependence).
Pharmaceutical opioid dependent people did not include those
who were solely taking pharmaceutical opioids in the context of
opioid substitution treatment (e.g. studies of people who were al-
ready in methadone treatment). Where participants were reported
to be ’opioid dependent’, as opposed to specifically dependent on
pharmaceutical opioids, the main opioid used prior to treatment
entry must have been a pharmaceutical opioid. We excluded stud-
ies examining opioid treatments primarily for pain and not for the
treatment of opioid dependence.
Where study populations were not exclusively comprised of pri-
mary pharmaceutical opioid dependent people, at least 80% of
the study participants must have reported pharmaceutical opioids
as their primary substance for the parent study data to be included
in the analysis. Where subpopulations of pharmaceutical opioid
dependent people do not comprise 80% of the study population,
we requested data for sub-analysis, with only participants meeting
the above criteria (i.e. dependent on pharmaceutical opioids, or
7Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
opioid dependent with the main opioid used being a pharmaceu-
tical opioid) included in the analysis. We contacted study authors
where necessary to confirm levels of use of pharmaceutical opi-
oids. Studies with mixed populations of opioid dependent people
must have recruited at least 10 people who were dependent on
pharmaceutical opioids for re-analyses of data to be included in
the review.
Types of interventions
We included studies of maintenance opioid agonist treatments,
where maintenance was defined as at least 30 days of opioid ago-
nist treatment. We included trials that made the following com-
parisons:
1. full opioid agonists (methadone, morphine, oxycodone,
LAAM, or codeine) versus different full opioid agonists or partial
opioid agonists (buprenorphine) for maintenance treatment;
2. full or partial opioid agonist maintenance versus placebo,
detoxification only, or psychological treatment (without opioid
agonist treatment).
Types of outcome measures
Outcome measures were not considered as part of the eligibility
criteria.
Primary outcomes
1. Illicit opioid use, as measured by: days of unsanctioned
opioid use at the end of the intervention period.
2. Illicit opioid use at end of treatment completion (defined as
point prevalence of opioid use at end of treatment by self report
and with urine drug screen).
3. Retention.
Secondary outcomes
1. Pain, assessed by validated scales such as the Brief Pain
Inventory (Cleeland 1991), and the McGill Pain Questionnaire
(Melzack 1975).
2. Risk behaviours (injecting, sexual, polydrug use, overdoses,
or hospital admissions).
3. Adverse effects (participants experiencing any adverse event,
or serious adverse event).
4. Aberrant opioid related behaviours (e.g. seeing multiple
doctors for extra opioid medication, lost medication,
unauthorised dose escalations).
5. Employment.
6. Quality of life, as assessed by validated scales such the
World Health Organization Quality of Life (WHOQOL) or
WHOQOL-BREF (WHO 1997).
7. Physical health, as assessed by validated scales such as the
36-item Short Form (SF-36) (Ware 1992)
8. Psychological health, as assessed by validated scales such as
the SF-36 (Ware 1992), Kessler Psychological Distress Scale
(K10) (Kessler 2002), or Depression and Anxiety Stress Scale
(DASS) (Lovibond 1995).
Outcomes were either self reported or objectively measured.
Search methods for identification of studies
Electronic searches
A search strategy was developed in consultation with a drug and
alcohol research information specialist, and search terms revised
appropriately for each database to take account of differences in
controlled vocabulary and syntax rules (Appendix 1).
We searched:
1. Cochrane Drugs and Alcohol Group’s Specialised Register
of Trials; May 2015;
2. the Cochrane Central Register of Controlled Trials
(CENTRAL, 2015, Issue 5);
3. PubMed (January 1966 to May 2015);
4. EMBASE (Ovid) (January 1974 to May 2015);
5. CINAHL (EBSCOhost) (1982 to May 2015);
6. ISI Web of Science (1900 to May 2014);
7. PsycINFO (Ovid) (1806 to May 2014).
Searching other resources
We search abstracted databases including the National Insti-
tute on Drug Abuse/College on Problems of Drug Dependence
(NIDA/CPDD) abstracts, as well as clinical trial registers Clini-
calTrials.gov (www.clinicaltrials.gov); World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP)
(www.who.int/ictrp/en).
We searched the reference lists of all relevant papers to identify
further studies, in addition to contacting the authors of all in-
cluded studies to enquire if there were other relevant published
or unpublished studies. All searches included English and non-
English language literature.
Data collection and analysis
Selection of studies
One review author reviewed the titles and abstracts identified by
the above searches. We requested the full text of each potentially
relevant article, and two review authors independently assessed the
studies for inclusion. Where the two review authors were unable
to reach agreement following their independent review of the full
text, a third review author assessed the studies to assist in reaching
consensus.
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Data extraction and management
Two review authors independently extracted data using a data
collection form, with a third review author involved where there
was disagreement to assist in reaching consensus.
We extracted information about the number of participants
treated; drug and dosing regimen; study design; study duration and
follow-up; and outcomes listed at including pain, substance use
measures, treatment retention, risk behaviours, employment, qual-
ity of life, physical and psychological health, and adverse events
(participants experiencing any adverse event, or serious adverse
event) from each study and recorded them on a data extraction
sheet.
We attempted to collect and utilise the most detailed numerical
data that might have facilitated similar analyses of included stud-
ies. Where 2×2 tables or means and standard deviations were not
available, we used effect estimates (e.g. odds ratios, regression coef-
ficients), confidence intervals (CI), test statistics (e.g. t, F, Z, Chi2)
or P values in the analyses (see also Measures of treatment effect).
Assessment of risk of bias in included studies
We performed the risk of bias assessment for RCTs using the cri-
teria recommended by the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). This comprises a two-part
tool addressing seven specific domains, namely sequence genera-
tion and allocation concealment (selection bias), blinding of par-
ticipants and providers (performance bias), blinding of outcome
assessor (detection bias), incomplete outcome data (attrition bias),
selective outcome reporting (reporting bias), and other sources of
bias. The first part of the tool involves describing what was re-
ported to have happened in the study. The second part of the tool
involves assigning a judgement relating to the risk of bias for that
entry, in terms of low, high, or unclear risk. To make these judge-
ments, we used the criteria indicated by the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), adapted to
the addiction field. See Appendix 2 for details.
The tools addressed the domains of sequence generation and allo-
cation concealment (avoidance of selection bias) by a single entry
for each study.
We considered blinding of participants, personnel, and outcome
assessor (avoidance of performance bias and detection bias) sepa-
rately for objective outcomes (e.g. retention, substance use mea-
sured by urine analysis, participants relapsed at the end of follow-
up, participants engaged in further treatments) and subjective out-
comes (e.g. duration and severity of signs and symptoms of with-
drawal, participant self reported use of substance, adverse effects,
social functioning as integration at school or at work, family rela-
tionship).
We considered incomplete outcome data (avoidance of attrition
bias) for all outcomes except for retention, which is often the
primary outcome measure in trials on addiction.
Grading the evidence
We assessed the overall quality of the evidence for the primary
outcome using the Grading of Recommendation, Assessment, De-
velopment and Evaluation Working Group (GRADE) system.
GRADE developed a system for grading the quality of evidence
that takes into account issues not only related to internal validity
but also to external validity, such as directness, consistency, im-
precision of results, and publication bias (GRADE 2004; Guyatt
2008; Guyatt 2011). We presented the main findings of the re-
view in the ’Summary of findings’ tables, which present results in
a transparent and simple tabular format. In particular, the tables
provide key information concerning the quality of evidence, the
magnitude of effect of the interventions examined, and the sum
of available data on the main outcomes.
The GRADE system uses the following criteria for assigning grades
of evidence.
1. High: we are very confident that the true effect lies close to
that of the estimate of the effect.
2. Moderate: we are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
3. Low: our confidence in the effect estimate is limited: the
true effect may be substantially different from the estimate of the
effect.
4. Very low: we have very little confidence in the effect
estimate: the true effect is likely to be substantially different from
the estimate of effect.
Grading is decreased for the following reasons.
1. Serious (-1) or very serious (-2) limitation to study quality.
2. Important inconsistency (-1).
3. Some (-1) or major (-2) uncertainty about directness.
4. Imprecise or sparse data (-1).
5. High probability of reporting bias (-1).
Grading is increased for the following reasons.
1. Strong evidence of association - significant risk ratio (RR)
of greater than 2 (less than 0.5) based on consistent evidence
from two or more observational studies, with no plausible
confounders (+1).
2. Very strong evidence of association - significant RR of
greater than 5 (less than 0.2) based on direct evidence with no
major threats to validity (+2).
3. Evidence of a dose response gradient (+1).
4. All plausible confounders would have reduced the effect
(+1).
Measures of treatment effect
Where possible, we expressed the treatment effect for each di-
chotomous outcome as a risk ratio (RR) with 95% confidence
intervals (CI). Where there was a comparable consistent outcome
measure (e.g. days of opioid use), we expressed the treatment ef-
fect for each continuous outcome as a mean difference (MD) with
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95% CIs. Where there was variability in outcome measure (e.g.
quality of life scales, risk behaviour measures, or pain scales), we
expressed the treatment effect for each continuous outcome as a
standardised mean difference (SMD) with 95% CIs.
Unit of analysis issues
For trials with multiple treatment arms, we combined groups to
allow single pair-wise comparisons.
Dealing with missing data
Where there appeared to be an important amount of missing data,
we described the possible effects of the missing data in the ’Dis-
cussion’ section and ’Summary of findings’ tables.
Assessment of heterogeneity
We considered clinical heterogeneity (variability in the partici-
pants, interventions, and outcomes studied) and methodological
heterogeneity (variability in study design and risk of bias), which
we discussed in the ’Summary of findings’ tables.
We conducted meta-analysis were studies were sufficiently homo-
geneous in terms of participants, interventions, and outcomes to
provide a meaningful summary. Where this was not the case, and
the heterogeneity of the included studies precluded a meta-analy-
sis being performed, we described the relevant studies separately.
To assess heterogeneity, initially we inspected the results graphi-
cally. A P value of the test lower than 0.10 or an I2 statistic of at
least 50% indicated significant statistical heterogeneity.
Assessment of reporting biases
We planned to use funnel plots (plots of the effect estimate from
each study against the standard error) to assess the potential for
bias related to the size of the trials, which could indicate possible
publication bias. As the search identified too few studies to be
included in a meta-analysis, we did not use funnel plots. In future
updates of this review if sufficient studies are included in meta-
analyses (i.e. more than 10), we will use funnel plots.
Data synthesis
We summarised the key findings of studies descriptively before
considering if studies were appropriate for quantitative meta-anal-
ysis. We contacted study authors where we required additional in-
formation to enable inclusion of studies in meta-analyses.
We undertook statistical analysis using Review Manager 5 (
RevMan 2012).
We combined the outcomes of the individual trials through meta-
analysis where possible (depending on the comparability of in-
terventions and outcomes between trials) using of a random-ef-
fects model as variability was expected between the studies. Where
meta-analysis was not possible, we reported a narrative synthesis
of the findings.
Subgroup analysis and investigation of heterogeneity
The search did not identify a sufficient number of studies to enable
planned subgroups of participants to be examined and investigated
for potential sources of heterogeneity:
1. with and without chronic pain;
2. with and without a history of heroin use;
3. with and without a history of injecting drug use;
4. with and without mental health problems.
We will consider the possibility of subgroup analyses when we
update the review and additional studies are available.
Sensitivity analysis
Where the effect of a decision on the outcome of the review was
uncertain (e.g. the decision to include or exclude a study remained
unclear, or the impact of unavailable data on the findings was
uncertain), we conducted a sensitivity analysis with the results
described in text.
To incorporate risk of bias assessment in the review process, we
planned to plot intervention effect estimates for different out-
comes stratified for risk of bias for each item; however, we found
insufficient numbers of studies to warrant this process for the two
planned comparisons. For future updates of this review, if differ-
ences in results are present among studies at different risk of bias,
we will perform sensitivity analysis, excluding studies at a high risk
of bias. We will also perform subgroup analysis for studies at a low
and unclear risk of bias.
R E S U L T S
Description of studies
See Characteristics of included studies table.
Results of the search
We identified 9076 studies through the electronic and other
searches. After removing duplicates, 6515 titles and abstracts re-
mained. We examined the full text or contacted study authors (or
both) of 49 records, excluding 43 records at this stage, identify-
ing six studies to be included in the analysis (See Figure 1). Sev-
eral full texts that were reviewed indicated studies had recruited
populations of ’opioid dependent people’ without specifying the
primary opioid used (e.g. whether the participant was dependent
on a pharmaceutical opioid, heroin, or opium). In each of these
papers, where the full text did not explicitly indicate that the par-
ticipants were dependent on pharmaceutical opioids, the review
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authors (SN, BL) contacted the study authors to determine if the
study met eligibility criteria with respect to the opioid used being
a pharmaceutical opioid. We included studies where the primary
opioid of concern was clearly identified as a pharmaceutical opioid
or where the study population included at least 10 participants that
were dependent on pharmaceutical opioids and data were avail-
able to enable analyses of the study data only for those participants
that were dependent on pharmaceutical opioids. Where authors
were unable to provide further information on the primary drug
of concern (other than being an opioid), or where we received no
response, we did not include the study.
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Figure 1. Study flow diagram.
12Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
We identified six RCTs that met the inclusion criteria (607 partic-
ipants). Three studies compared methadone and buprenorphine
(Ahmadi 2003; Neumann 2013; Saxon 2013), and three stud-
ies compared buprenorphine maintenance to either buprenor-
phine taper (in addition to psychological treatment) (Woody
2008; Fiellin 2014) or brief intervention and referral to treatment
(D’Onofrio 2015). The mean duration of the trials was 105 days.
Five of the six studies were conducted in an outpatient setting.
One study recruited participants who were admitted to hospital,
with one group randomised to commence buprenorphine as an
inpatient while the other two groups offered a brief intervention
and treatment referral information (D’Onofrio 2015). Neumann
2013 recruited a population of people with chronic non-cancer
pain and opioid dependence. All other studies recruited partici-
pants with dependence on pharmaceutical opioids, and one study
specifically recruited participants that were injecting buprenor-
phine (Ahmadi 2003).
Data from three studies were re-analyses of parent studies to in-
clude only data from participants who were dependent on phar-
maceutical opioids; two studies provided data for analyses through
the CTN data share website (Woody 2008; Saxon 2013), and
for one study, the study statistician provided the data for partici-
pants who were dependent on pharmaceutical opioids (D’Onofrio
2015). Fiellin 2014 also provided additional data to facilitate anal-
yses with comparable outcome measures across the studies. Data
for two studies were drawn directly from the published papers
(Ahmadi 2003; Neumann 2013).
Five studies were conducted in the US and one study was con-
ducted in Iran (Ahmadi 2003). Five studies recruited adults, and
one study examined young people aged 15 to 21 years (Woody
2008).
Overall, the participants in the studies were 77% male and had a
mean age of 31.6 years. The mean duration of the studies com-
paring different opioid maintenance treatments (three studies that
compared methadone to buprenorphine) was 24 weeks, and the
mean duration of studies comparing a maintenance treatment
(three studies with buprenorphine maintenance) to detoxification
or psychological treatment was 10 weeks.
Excluded studies
Of the studies that we excluded during full text review, we excluded
three studies because all participants received the same opioid ago-
nist (or partial agonist) medication, meaning that no comparison
was possible: one study of buprenorphine for prescription opioid
dependence because the study was an adaptive study design where
the randomised trial component compared adjunctive counselling
to standard care, and all participants received buprenorphine (re-
sulting in there being no non-opioid agonist comparison group)
(Weiss 2011). Fiellin 2006 described that all participants received
buprenorphine, hence there was no non-agonist arm for compar-
ison. Chopra 2009 also examined different psychosocial adjunct
treatments where all participants received buprenorphine.
Four studies contained prescription opioid dependent people in
their population, but the number was too small (e.g. two or three
participants) to permit meaningful analyses of the prescription
opioid dependent participants across different treatment condi-
tions (Liebschutz 2013), or dependence to pharmaceutical opioids
was unable to be confirmed where participants were using multi-
ple opioids (Strain 1996; Kristensen 2005; Piralishvili 2015). Two
further studies recruited pharmaceutical opioid dependent partic-
ipants to the study; we requested data to perform analyses for only
those dependent on pharmaceutical opioids but they were not
available at the time of this review (Ling 2010; Rosenthal 2013).
Three studies did not administer maintenance opioid agonists (
Stitzer 1983; Amass 1994; Sigmon 2013), and three studies were
not RCTs (Batki 1998; Gossop 2001; Hoffmann 2014).
The remainder of the excluded studies had populations of opioid
dependent people primarily using heroin (see Excluded studies).
Risk of bias in included studies
Figure 2 and Figure 3 present a summary of the assessed risk of
bias for each of the included studies.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
No studies had high risk of selection bias. All included studies
were RCTs. For two studies, the method of sequence generation
was unclear (Ahmadi 2003; Saxon 2013), and for three studies,
the method of allocation concealment was unclear (Ahmadi 2003;
Neumann 2013; Saxon 2013). The remaining studies had low risk
of random sequence or allocation bias.
Blinding
None of the studies were double blinded studies (most studies were
described as open-label studies), with all studies having either a
high or unknown risk of bias.
Incomplete outcome data
All studies reported data on retention. For other outcomes mea-
sures, some studies only presented data on treatment completers
(Neumann 2013), or had differences in the number of partici-
pants retained across groups, which potentially introduced bias
(Fiellin 2014; D’Onofrio 2015). Two studies had a low risk of bias
(Woody 2008; Saxon 2013).
Selective reporting
Four studies had a low risk of reporting bias, with prospectively
published protocols available or prospective clinical trial registra-
tion including describing main outcome measures or data pub-
lished on open access websites, or a combination of these (Woody
2008; Neumann 2013; Saxon 2013; D’Onofrio 2015). One study
only reported on one outcome measure, retention (Ahmadi 2003).
Effects of interventions
See: Summary of findings for the main comparison Full opioid
agonists versus different full opioid agonists or partial opioid
agonists (methadone versus buprenorphine) for maintenance;
Summary of findings 2 Full or partial opioid agonist maintenance
versus placebo, detoxification only or psychological treatment
(buprenorphine maintenance compared to taper or treatment as
usual)
See Summary of findings for the main comparison; Summary of
findings 2. We presented results for the two main comparisons:
1. opioid agonists versus other opioid agonists (or partial
agonists) for maintenance treatment;
2. full or partial opioid agonists versus placebo, detoxification,
or psychological treatment (without maintenance agonist
treatment).
The results in the ’Summary of findings’ tables include the primary
outcomes measures of opioid use and retention in treatment.
Full opioid agonists versus different full opioid
agonists or partial opioid agonists
We found three studies, all comparing methadone versus
buprenorphine (with or without naloxone) (Ahmadi 2003;
Neumann 2013; Saxon 2013). We found no studies examining
opioids agonists other than methadone or buprenorphine.
Primary outcomes
Illicit opioid use
There was no significant difference in days of unsanctioned opi-
oid use (MD -1.41 days, 95% CI -3.37 to 0.55; one study; 129
participants) (Analysis 1.1).
There was no significant difference in point prevalence use at the
end of treatment (urine-analysis results) (RR 0.81, 95% CI 0.56
to 1.18; two studies; 196 participants) (Analysis 1.2).
There was no significant difference in point prevalence use at the
end of treatments (self reported)(RR 0.37, 95% CI 0.08 to 1.63;
two studies; 155 participants) (Analysis 1.3).
Retention
There was no significant difference in retention (number of par-
ticipants retained at end of treatment) (RR 0.69, 95% CI 0.39 to
1.22; three studies; 360 participants) (Analysis 1.4).
Secondary outcomes
Pain
Two studies with 152 participants found no significant differ-
ence in pain using different measures (improvement from baseline
pain and mean bodily pain). They found no significant difference
(SMD 0.11, 95% CI -0.22 to 0.43) (Analysis 1.5).
Risk behaviours
One study with 170 participants found no significant difference in
risk behaviours (RR 0.52, 95% CI 0.02 to 12.64) (Analysis 1.6).
Adverse effects
Two studies examined adverse effects but in different ways:
Neumann 2013 described self reported adverse effects and serious
adverse events, Saxon 2013 examined serious adverse effects. The
two studies, with data from 196 participants, found no significant
difference (RR 1.10, 95% CI 0.64 to 1.91) (Analysis 1.7).
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Aberrant opioid related behaviours
None of the studies reported aberrant opioid related behaviours.
Employment
None of the studies reported on employment.
Quality of life
None of the studies reported an overall quality of life score.
Physical health
One study found no significant difference in mean physical func-
tioning (SF-36) (MD 1.28, 95% CI -3.83 to 6.39; 127 partici-
pants) (Analysis 1.8).
Psychological health
One study found no significant difference in mental health func-
tioning (SF-36) (MD -2.13, 95% CI -10.06 to 5.80; 127 partici-
pants) (Analysis 1.9).
Full or partial opioid agonist maintenance versus
placebo, detoxification only, or psychological
treatment (without opioid agonist treatment)
We found three studies, all comparing buprenorphine mainte-
nance treatment to a control condition. We found no studies using




There was no significant difference in days of unsanctioned opioid
use (reported as mean days in past 7 or 30 days: SMD -0.31; 95%
CI -0.66 to 0.04; two studies; 133 participants) (Analysis 2.1).
There was a significant difference in favour of buprenorphine
maintenance treatment for point prevalence use at the end of treat-
ment (urine-analysis results) (RR 0.63, 95% CI 0.43 to 0.91; three
studies, 206 participants) (Analysis 2.2).
There was a significant difference in favour of buprenorphine
maintenance treatment for point prevalence use at the end of treat-
ments (self reported) RR 0.54, 95% CI 0.31 to 0.93; three stud-
ies, 204 participants). When the analysis excluded results from
Woody 2008 due to evidence of heterogeneity (degrees of freedom
(df ) = 2; P value = 0.12; I2 = 52%) the result of the meta-analyses
was unchanged favouring buprenorphine maintenance (RR 0.66,
95% CI 0.49 to 0.89; two studies; 177 participants; P value =
0.81; I2 = 0%) (Analysis 2.3).
Retention
There was a significant difference in favour of buprenorphine
maintenance treatment for retention (number of participants re-
tained at end of treatment) (RR 0.33, 95% CI 0.23 to 0.47; three
studies; 247 participants) (Analysis 2.4).
Secondary outcomes
Pain
There was no significant difference in the proportion of partici-
pants who reported ’moderate’ or ’extreme’ pain or discomfort at
week eight (RR 0.52, 95% CI 0.27 to 1.01; one study; 36 partic-
ipants)(Analysis 2.5).
Risk behaviours
There was no significant difference in events of injecting risk be-
haviour (RR 0.38, 95% CI 0.04 to 3.54; two studies; 98 partici-
pants) (Analysis 2.6).
Adverse effects
Outcomes were measured differently across two studies, one study
reported protective transfers Fiellin 2014 and one study reported
serious adverse events Woody 2008. 166 participants: with find-
ings favouring the buprenorphine maintenance (RR 0.19, 95%CI
0.06, 0.57). See Analysis 2.7.
Aberrant opioid related behaviours
None of the studies reported aberrant opioid related behaviours.
Employment
None of the studies reported on employment.
Quality of life
None of the studies reported an overall quality of life measure.
Physical health
There was a significant difference in favour of buprenorphine
maintenance treatment for mean ratings of physical health on the
EQ Visual Analogue Scale (a scale of self reported health state out
of 100) at week eight (MD 31.08, 95% CI 12.40 to 49.76; one
study; 36 participants) (Analysis 2.8).
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Psychological health
There was no significant difference in proportions of participants
reporting moderate or extreme anxiety and depression (as mea-
sured with the EQ-5D (EuroQol five dimensions questionnaire))
at week eight (RR 0.89, 95% CI 0.53 to 1.50; one study; 36 par-
ticipants) (Analysis 2.9).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Full or partial opioid agonist maintenance versus placebo, detoxification only or psychological treatment (buprenorphine maintenance compared to taper or treatment as
usual)
Patient or population: pharmaceut ical opioid dependent people
Intervention: opioid agonist
Comparison: detoxif icat ion/ placebo
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was ident if ied in popu-
lat ions, of note is that
the study by Ahmadi
2003 recruited peo-
ple who were inject ing
buprenorphine, and pre-
dominant ly had histo-
ries of opium or heroin
use prior to buprenor-
phine. Results were
not changed when the
analyses excluded this
study (i.e. no dif ference
between buprenorphine
and methadone when
this study was included
or excluded)
631 per 1000 208 per 1000
(145 to 297)
-
769 per 1000 254 per 1000
(177 to 362)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent











































































































Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Studies were open label, dif f erences in retent ion were reported between the groups result ing in dif f erences in missing data
on some variables.
2 One study was examining dif ferent methods of referral to treatment in non-treatment seeking people who presented to













































































































D I S C U S S I O N
Summary of main results
The studies identified compared methadone versus buprenorphine
maintenance treatment (three studies), and buprenorphine main-
tenance treatment versus detoxification or psychological treatment
(without maintenance agonist treatment); two studies where the
comparison was buprenorphine taper and one study where the
control condition was brief intervention and referral). In total,
the review included six studies with 604 participants. The quality
of the evidence was generally low to moderate (see Summary of
findings for the main comparison; Summary of findings 2) with all
studies being RCTs that were not double blind. Sample sizes were
generally small, from 53 to 204 participants. The meta-analyses
included data for both comparisons for the primary outcomes of
opioid use and retention.
There was moderate quality evidence finding no significant differ-
ences in self reported opioid use or opioid positive urine drug tests
between methadone and buprenorphine. There was low quality
evidence that there was no difference in retention between meth-
adone and buprenorphine. These are commonly considered some
of the important outcomes for treatment of pharmaceutical opi-
oid dependence. As evidence did not favour either of these treat-
ments, other clinician or treatment system factors may contribute
to the choice of pharmacotherapy for patients, including patient
preference, safety, and availability of medications.
Where buprenorphine maintenance was compared with detoxifi-
cation or other psychological treatment (in the absence of mainte-
nance opioid pharmacotherapy), low to moderate quality evidence
favoured maintenance buprenorphine treatment with less self re-
ported opioid use and fewer opioid positive urine tests combined
with greater retention. These findings suggest that where retention
and substance outcomes are important to patient and clinician,
there appear to be advantages in maintenance agonist treatment.
Overall completeness and applicability of
evidence
There was enough consistency in the way the studies collected and
reported primary outcome measures to enable pooling data on
the key outcomes measures. Missing data introduced the potential
for bias in opioid use outcome measures. An important limitation
to generalisability is study location. Five of the six studies were
conducted in the US, making it difficult to know how these find-
ings may apply to people dependent on pharmaceutical opioids in
other settings.
Quality of the evidence
The studies in this review were generally either small or the sample
size was small once the population was restricted to only people
that were dependent on pharmaceutical opioids. Two studies had
larger sample sizes; Saxon 2013 (170 participants in the analy-
ses of only pharmaceutical opioid dependent people) and Ahmadi
2003 (204 participants, although this study reported only one out-
come). The study by Ahmadi 2003 contributed around one-third
of the sample size, and represented a population of buprenorphine
injectors. As such, the population in this study may differ from
the populations of the other two studies. Sensitivity analyses con-
firmed that the exclusion of this study did not change the overall
result of the meta-analyses. No studies had high risk of selection
bias, though none of the studies were double blinded. Four out of
six studies had low risk of reporting bias. See Figure 2 and Figure
3.
One of the studies had the primary outcome of ’enrolment in ad-
diction treatment 30 days after randomisation’, as the study was
examining commencing buprenorphine as an inpatient versus two
other conditions where participants received some form of brief
intervention and referral to addiction treatment (these two other
non-buprenorphine groups were combined in the present analy-
ses) (D’Onofrio 2015). As such, the evidence from this study on
opioid use outcomes could be considered indirect as the study did
not directly aim to reduce opioid use. Finally, data for three of the
six studies were drawn from existing larger studies of opioid de-
pendent people, rather than from studies specifically developed to
examine the effectiveness of these interventions for pharmaceutical
opioid dependent people (Woody 2008; Saxon 2013; D’Onofrio
2015).
Potential biases in the review process
There is the possibility that studies with negative findings on phar-
macotherapy may be less likely to be published, which could po-
tentially favour the finding of published studies that demonstrate
an effect of pharmacotherapy treatments. We identified no con-
ference abstracts of unpublished studies to confirm if this is the
case.
Agreements and disagreements with other
studies or reviews
The finding of no difference in retention between methadone and
buprenorphine is in contrast to findings reported in studies of
predominantly people dependent on heroin, where Mattick 2014
found evidence in favour of methadone retaining more partici-
pants in treatment. Due to the small sample sizes in this review,
there is the possibility that the review was underpowered to detect
a difference.
Findings appear consistent with a larger adaptive study design
that also appeared to favour longer periods of buprenorphine
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treatment, with poorer outcomes following buprenorphine taper
among pharmaceutical opioid dependent people (Weiss 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There was low quality evidence supporting the use of maintenance
agonist pharmacotherapy for pharmaceutical opioid dependence.
The current data suggest that methadone or buprenorphine are
equally effective. As evidence did not favour either of these treat-
ments over the other, other clinician or treatment system factors
may contribute to the choice of pharmacotherapy for patients, in-
cluding patient preference, safety, and availability of medications.
Maintenance treatment with buprenorphine may be more effective
than detoxification or psychological treatments (or both).
Due to the overall low to moderate quality of the evidence and
smaller sample sizes, there is the possibility that the further research
may change these findings.
Implications for research
There is a high prevalence of chronic pain among pharmaceuti-
cal opioid dependent people (Lusted 2013); however, only one
small study examined outcomes among people with concurrent
pain and opioid dependence (Neumann 2013). Larger studies
are needed to examine all outcomes, and particularly for people
with pain and opioid dependence, in addition to including stan-
dardised measures of pain severity and pain interference as sec-
ondary outcomes measures in randomised controlled trials of opi-
oid treatments where populations with pain are recruited (Turk
2008). Growing evidence supports the use of multi-modal treat-
ment strategies for pain, as opposed to relying solely on opioids
for pain management. Expanding the evidence for non-drug and
adjuvant medication strategies to reduce the reliance on opioids
for pain management will be important areas for future work. In
addition, studies that specifically recruit pharmaceutical opioid
dependent people will add to the evidence base that is currently
formed in large part by secondary data analyses from previously
completed clinical trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by year of study]
Ahmadi 2003
Methods Open label randomised controlled trial
Participants Participants had reported daily buprenorphine injection for at least 6 months. Most
(80%) had a history of heroin or opium dependence prior to buprenorphine injection.
All participants were male, mean age of 31.2 years (range 17-53). No current use of
substances was reported
Interventions Methadone 50 mg (n = 68)
Buprenorphine 5 mg (n = 68)
Naltrexone 50 mg (n = 68)
For 12 weeks
Outcomes Retention
Notes No other outcome measures reported. A second publication appeared to report findings
from the same study. Included only the first publication on the study. Funding for the
study not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was provided to en-
able assessment
Allocation concealment (selection bias) Unclear risk Insufficient information was provided to en-
able assessment
Blinding of participants and personnel
(performance bias) Objective measures
Unclear risk Insufficient information was provided to en-
able assessment
Blinding of outcome assessor (detection
bias) Subjective outcomes
Unclear risk Insufficient information was provided to en-
able assessment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information was provided to en-
able assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information was provided to en-
able assessment
Selective reporting (reporting bias) High risk Information was only reported on retention
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Woody 2008
Methods Open label randomised controlled trial of buprenorphine (+ naloxone) maintenance
compared with buprenorphine detoxification
Participants Opioid dependent youths (aged 15-21 years). Analyses from unpublished data reported
represents only those participants (n = 53) who reported that a pharmaceutical opioid
was their main drug problem. Mean age of participants reporting pharmaceutical opioid
as a main drug problem 20.0 (SD 1.3) years old, and 64% male
Interventions Buprenorphine-naloxone + counselling (n = 27) for 12 weeks
Buprenorphine detoxification + counselling (n = 26) for 14 days
Outcomes Main outcome measure was opioid positive urine tests at weeks 4, 8, and 12
Notes All outcomes reported in this analysis were for week 8 as buprenorphine taper began in
week 9, meaning at week 12 participants were no longer in maintenance treatment
Disclosures: Quote: “Dr Woody reported being a member of the RADARS [Researched
Abuse, Diversion and Addiction-Related Surveillance] postmarketing study external ad-
visory group whose job is to assess abuse of prescription medications. Denver Health
administers RADARS and Abbott, Cephalon, Endo, Pricara/Ortho-McNeil, Purdue
Pharma, and Shire subscribe to its data. Dr Woody reported that Ortho-McNeil and
Purdue Pharma funded similar work by him prior to his joining RADARS. Dr Woody
reported that Schering-Plough, the European distributor for buprenorphine-naloxone,
funded his travel costs to meetings in Sweden and Finland in June 2008 to present data
from this study. Dr Bogenschutz reported receiving research funding from Forest and
Lilly and having a confidentiality agreement with Lilly. Dr Forman reported being a
faculty member at the University of Pennsylvania and co-principal investigator with Dr
Woody on the Delaware Valley Node of the NIDA Clinical Trials Network until Decem-
ber 2005 when he joined Alkermes. Dr Patkar reported being a consultant to Bristol-
Meyers Squibb, GlaxoSmithKline, and Reckitt Benckiser and being on the speakers’ bu-
reau for and receiving honoraria from Bristol-Meyers Squibb, Forest, GlaxoSmithKline,
Janssen, Jazz Pharmaceuticals Lundbeck, McNeil Consumer & Specialty Inc, Organon,
and Pfizer. Dr Publicker reported having been a speaker for Cephalon, Forest, and Reckitt
Benckiser. Dr McNicholas reported having conducted training programs to certify physi-
cians in the use of buprenorphine. Her expenses have been paid by unrestricted grants
to universities that were often provided by Reckitt Benckiser. Dr Fudala reported having
been employed by the University of Pennsylvania and Philadelphia VA Medical Center
from 1991 until he joined Reckitt Benckiser in June 2005 and reported having
been a consultant to Johnson & Johnson and Purdue Pharma”
This study was supported by the NIDA and Reckitt Benckiser provided medication for
the study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization occurred through
an automated 24-hour service at the Vet-
erans Affairs Cooperative Studies Program
in Perry Point, Maryland, that was pro-
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Woody 2008 (Continued)
grammed to randomise patients separately
by site”
Allocation concealment (selection bias) Low risk Central randomisation procedures de-
scribed above, condition could not be fore-
seen by staff
Blinding of participants and personnel
(performance bias) Objective measures
High risk Quote: “Research assistants likely know
group assignments because the study was
not blinded”
Open label study
Blinding of outcome assessor (detection
bias) Subjective outcomes
High risk Quote: “Research assistants likely know
group assignments because the study was
not blinded”
Open label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Research assistants likely knew
group assignments because the study was
not blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Investigators used multiple statistical ap-
proaches to examine the impact of missing
data on their results and it appears the re-
sults of these analyses did not alter the re-
sults of the study findings
Quote: “A pattern-mixture model was used
to assess the impact of missing data on
urine test results. Pattern mixture models
extend the basic repeated measures by in-
cluding a variable that describes the main
patterns of missing data as a main effect and
an interaction with other variables (week
and group). Significant interactions with
the missing data indicator on the main vari-
ables suggest that its effects differ across
levels of missing data and that missing
data may not be ignorable. Following sug-
gested guidelines,23 we used time of last
data provision (a categorical variable rep-
resenting week 4, 8, or 12) as the miss-
ing variable. Another approach often taken
is to impute missing tests as positive. If
results obtained for the original and im-
puted models differ substantially, missing
data may not be ignorable. Both meth-
ods were used to evaluate the effects of
data on the primary outcome wherein miss-
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Woody 2008 (Continued)
ing urine test results were counted as opi-
oid positive. A GEE [generalised estimat-
ing equation] model that ignored missing
data showed a marginal group × time in-
teraction ( = 4.93, P = .09). While not at-
taining the usual 5% significance, it likely
reflected a lack of power for interaction ef-
fects rather than constant treatment effects
at each time point.” “Because there were no
interactions pertaining to dropout time, re-
sults suggested that missing data were not
invalidating the group effect”
Selective reporting (reporting bias) Low risk Protocol and data were available on an open
access datashare website
Saxon 2013
Methods Open label randomised controlled trial of methadone vs. buprenorphine
Participants Reported analyses of unpublished data only for participants that used only pharmaceu-
tical opioids in the 30 days prior to the study (n = 170). Sample was 61% (n = 104)
male, mean age 34.4 years (SD 10.1) at baseline and 83% white with no difference
between randomisation groups on demographic characteristics. Participants who were
randomised to the buprenorphine group were less likely to report a history of heroin
use (odds ratio 0.465, 95% confidence interval 0.25 to 0.88). Past year dependence on
other substance was as follows: alcohol 7% (n = 11), cannabis 7% (n = 12), cocaine 8%
(n = 14), amphetamines 7% (n = 11), sedatives 7% (n = 12)
Interventions Methadone (n = 66)
Buprenorphine (n = 104)
24 weeks in a flexible dose schedule
Outcomes Primary outcome of the parent study was liver function at 24 weeks
Notes Financial interests disclosed. Quote: ”Andrew Saxon: Paid consultant to Reckitt
Benckiser Pharmaceuticals; Walter Ling: Paid consultant to Reckitt Benckiser Pharma-
ceuticals; R. Douglas Bruce: Research grant support from Gilead Sciences, Inc., Merck
& Co., Bristol Myers Squibb, Boehringer Ingelheim, Reckitt Benckiser Pharmaceuticals,
Abbott Laboratories, Pfizer, Inc., and honorarium from Reckitt Benckiser Pharmaceu-
ticals; Yuliya Lokhnygina: Paid consultant to Johnson & Johnson
Reckitt Benkiser provided some initial advice on the study design and supplied Suboxone.
The main study funding came from the
NIDA through the Clinical Trials Network
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Saxon 2013 (Continued)
Random sequence generation (selection
bias)
Unclear risk Study stated randomisation, no additional
information reported on sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Method of concealment not described
Blinding of participants and personnel
(performance bias) Objective measures
High risk Study reported to be an open label study
Blinding of outcome assessor (detection
bias) Subjective outcomes
High risk Study reported to be an open label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study reported to be an open label study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Figure 1 of the publication indicated that
there was more missing data from the
buprenorphine group; however, in the sub-
analyses, retention was comparable across
the groups suggesting that this was less
likely to influence the results presented in
this review
Selective reporting (reporting bias) Low risk Study protocol was available and expected
results were reported. Further, study data
available on datashare website
Neumann 2013
Methods Open label randomised controlled trial
Participants Participants eligible for randomisation were men and women aged ≥ 18 years with well
documented chronic non-malignant pain related to the spine or a large joint (e.g. hip,
knee, shoulder) and an addiction to prescription opioids. The sample (n = 54) was 54%
(n = 29) men, mean age 38.3 years (SD 9.7). 7 participants reported cocaine use at
baseline and 20 (36%) had a urine drug test that was positive for any other drug at
baseline
Interventions Sublingual buprenorphine/naloxone 4-16 mg/1-4 mg/day (experimental group) (n = 26)
Oral methadone tablets 10-60 mg/day (active comparator group) (n = 28); doses were
divided 1-4 times daily
Outcomes Pain and opioid use
Notes Results were reported for treatment completers only
The study was supported, in part, by a grant from the NIDA. Conflicts of interest were
not reported in the manuscript
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Neumann 2013 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised into 1 of 2
groups that were pre-determined by drawing
lots using a 3:3 ratio block randomisation pro-
cedure
Allocation concealment (selection bias) Unclear risk Method of concealment not described
Blinding of participants and personnel
(performance bias) Objective measures
High risk Quote: “This is a preliminary study ...that
was not a double-blind and double-dummy
study.” “This was an open-label trial without
a placebo and a control group. The outcomes
might have been different, if a placebo had
been used and the treatment conditions were
masked to the participants, to the clinicians
who provided care, and to the investigators
who collected the follow-up data”
No blinding was described
Blinding of outcome assessor (detection
bias) Subjective outcomes
High risk As above, open label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk As above, open label study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses only for completers; however, miss-
ing data balanced across the 2 intervention
groups (n = 15/28 missing for methadone
group and n = 13/26 missing for buprenor-
phine group), 13 completers in each group
Selective reporting (reporting bias) Low risk Outcomes were consistent with
those prospectively reported on clinicaltrials.
gov NCT00879996
Fiellin 2014
Methods Open label office-based trial of buprenorphine taper compared to buprenorphine main-
tenance
Participants People who were prescription opioid dependent, mean age 30.35 years (SD 9.16), 58%
male. At baseline cocaine abuse was reported by 12% (n = 13)
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Fiellin 2014 (Continued)
Interventions Buprenorphine stabilisation for 6 weeks followed by 3-week taper (n = 57)
Maintenance buprenorphine (n = 56) for 14 weeks
Outcomes Illicit opioid use, retention, and re-initiation of buprenorphine treatment
Notes Quote: “Dr Fiellin has received honoraria for serving on expert advisory boards to
monitor for diversion, misuse, and abuse of buprenorphine for Pinney Associates and
ParagonRx and has received honoraria from the American Society of Addiction Medicine
to serve as the medical director of the Physician Clinical Support Systems for Buprenor-
phine and Primary Care and from the American Academy of Addiction Psychiatry to
serve as a consultant to the Physician Clinical
Support Systems for Buprenorphine and Opioids. Drs Schottenfeld and Moore received
support from the Connecticut Mental Health Center, State of
Connecticut. Dr Barry has received compensation for expert testimony addressing ad-
diction and pain. No other disclosures were reported”
Funding was received from NIDA and a pharmaceutical company, Reckitt-Benckiser
Pharmaceuticals, provided
buprenorphine through the NIDA
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After the induction and stabiliza-
tion period, patients were randomly as-
signed in a 1:1 ratio to receive taper or
maintenance therapy (each described be-
low). An urn randomisation procedure un-
der the control of an investigator (B.A.M.
) who was not involved with enrolment or
assessment for eligibility was used to ensure
that the groups were similar with regard
to current cocaine abuse and urine samples
with findings negative for opioids and co-
caine at the time of randomisation”
Allocation concealment (selection bias) Low risk Quote: “Treatment allocation was commu-
nicated by an investigator not involved in
assessment for eligibility or randomization
who notified each patient of his or her treat-
ment assignment in a sequential manner”
Blinding of participants and personnel
(performance bias) Objective measures
High risk Quote: “Open label randomized clinical
trial”
Blinding of outcome assessor (detection
bias) Subjective outcomes
High risk Quote: “Open label randomized clinical
trial”
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Fiellin 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Open label randomized clinical
trial”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Patients in the taper group pro-
vided fewer urine samples than those in the
maintenance group (57.3% vs 78.2%; P =
.001). The results regarding the patient-re-
ported frequency of illicit opioid use are
based on 1044 assessments of the 1582 to-
tal possible assessments (66.0%) had all pa-
tients remained in treatment for the entire
14-week trial. Patients in the taper group
completed fewer patient-reported assess-
ments than those in the maintenance group
(56.9% vs 76.3%; P < .001)”
Selective reporting (reporting bias) Unclear risk Clinicaltrials.gov indicated some measures
that were collected were not included in the
primary outcome paper (e.g. reductions in
HIV risk; patient satisfaction, costs of ser-
vices). The main outcomes that would be
expected to be reported in a study of this
type were included in the main outcome
paper, suggesting that this may not repre-
sent bias
D’Onofrio 2015
Methods Randomised controlled trial (open label) of opioid dependent people presenting at emer-
gency departments
Participants Included in analyses were unpublished data for participants where a pharmaceutical
opioid was the primary opioid used (n = 82). The main study recruited participants who
were 75% male with a mean age of 31.4 years (SD 10.6). Data on other substance use
for the subset that used pharmaceutical opioids were not available
Interventions Referral to addiction treatment (n = 31)
Brief intervention and referral to addiction treatment (n = 24)
Brief intervention and commenced on buprenorphine as an inpatient (n = 27)
Outcomes Primary outcome was engagement in addiction treatment on the 30th day following
randomisation. Secondary outcomes collected at 30 days included self reported number
of days of illicit opioid use in the past 7 days, urine toxicology for illicit opioid use, HIV
risk taking behaviour, and use of addiction treatment services
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D’Onofrio 2015 (Continued)
Notes Quote: “The study was supported by grant 5R01DA025991 from the National Institute
on Drug Abuse (NIDA), and Reckitt-Benckiser Pharmaceuticals provided buprenor-
phine through NIDA”
Dr Fiellin reported having received honoraria from Pinney Associates “for serving on an
external advisory board monitoring the diversion and abuse of buprenorphine”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A computerized stratified ran-
domization procedure under the control of
an investigator (M.C.C.) who was not in-
volved with enrolment or assessment for el-
igibility was used to ensure that the groups
were balanced with regard to sex, cocaine
use in the last 30 days, and primarily pre-
scription opioid or heroin use”
Allocation concealment (selection bias) Low risk Quote: “ A computerized stratified ran-
domization procedure under the control of
an investigator (M.C.C.) who was not in-
volved with enrolment or assessment...”
Blinding of participants and personnel
(performance bias) Objective measures
Unclear risk Quote: “Data on all outcomes were col-
lected by research associates not involved in
the patients’ ED [emergency department]
care”
Not enough details were available to assess
risk (i.e. just because the participants were
not aware of the care in the ED did not
mean that they were not aware of the study
treatment)
Blinding of outcome assessor (detection
bias) Subjective outcomes
Unclear risk Quote: “Data on all outcomes were col-
lected by research associates not involved in
the patients’ ED [emergency department]
care”
Not enough details were available to assess
risk (i.e. just because the participants were
not aware of the care in the ED did not
mean that they were not aware of the study
treatment)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Data on all outcomes were col-
lected by research associates not involved in
the patients’ ED [emergency department]
care”
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D’Onofrio 2015 (Continued)
Not enough details were available to assess
risk (i.e. just because the participants were
not aware of the care in the ED did not
mean that they were not aware of the study
treatment)
Incomplete outcome data (attrition bias)
All outcomes
High risk For the main outcome paper, most data
would not have been affected by attrition
due to the statistical methods used
Quote: “We used the mixed-models pro-
cedure repeated measures linear models to
evaluate the differences between baseline
and 30-day follow-up in the number of
days per week of illicit opioid use, HIV
risk behaviors, and inpatient addiction ser-
vices across the study groups. This analyti-
cal approach uses all available data on each
randomized patient; therefore, all study pa-
tients, including those with missing data,
were included in the analyses; no imputa-
tions were required”
This suggests that for the main outcome pa-
per low risk would exist; however, authors
reported that there were more missing data
for the non-opioid agonist group, suggest-
ing analyses presented in this review may
be affected by attrition bias
Selective reporting (reporting bias) Low risk All measures prospectively reported on
Clinicaltrials.gov were reported in the main
outcome paper, in addition to those that
would be usually expected in this type of
study
HIV: human immunodeficiency virus; n: number of participants; NIDA: National Institute on Drug Abuse; SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Amass 1994 No opioid maintenance condition as per definition of maintenance in protocol
Anglin 2007 Participants were heroin dependent
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(Continued)
Batki 1998 Study was not a randomised controlled trial
Cameron 2006 Unable to determine if participants were dependent on pharmaceutical opioids
Chopra 2009 All participants received buprenorphine (i.e. not randomised to different opioid agonists, and no non-agonist
group), randomised to different conditions of contingency management to promote abstinence from illicit
opioid use
Eder 1998 Study participants were primarily heroin dependent
Fiellin 2006 All groups received buprenorphine, that is there was no non-agonist comparison group
Fischer 1999 Study participants were primarily heroin dependent
Fudala 2003 Study participants were primarily heroin dependent
Gossop 2001 Study was not a randomised controlled trial design
Gruber 2008 Participants were primarily using heroin
Hoffmann 2014 Observational study (not a randomised controlled trial)
Johnson 1992 Participants were primarily using heroin
Johnson 1995 Participants were primarily using heroin
Johnson 2000 Participants were primarily using heroin
Kakko 2003 Participants were primarily using heroin
Karp-Gelernter 1982 Participants were primarily using heroin
Kristensen 2005 Sub-analyses of participants that used only pharmaceutical opioids was not possible, though it was confirmed
that there were participants that used a combination of heroin and pharmaceutical opioids
Liebschutz 2013 Too few participants (< 10) were using only pharmaceutical opioid, precluding meaningful comparisons
Ling 1996 Participants were primarily using heroin
Ling 1998 Participants were primarily using heroin
Ling 2010 Data not available to perform analyses on only those participants who were dependent on pharmaceutical
opioids
Longshore 2005 Participants were primarily using heroin
Maremmani 1999 Unable to confirm if study met inclusion criteria from information available
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McKenzie 2012 Participants were primarily using heroin
Montoya 2004 Participants were primarily using heroin
Petitjean 2001 Full text described sample in terms of their heroin use, unable to confirm with authors if any participants
were primarily pharmaceutical opioid dependent people
Piralishvili 2015 Unclear if participants were dependent only on pharmaceutical opioids
Reimer 2011 Participants were primarily using heroin
Robertson 2006 Published paper did not indicate the primary opioid used by study participants, unable to confirm with study
authors
Rosenthal 2013 Data not available to perform analyses on only those participants who were dependent on pharmaceutical
opioids
Sees 2000 Participants were described as primarily using heroin. Unable to confirm with study authors if there were any
pharmaceutical opioid dependent participants recruited
Sigmon 2013 Study was not of maintenance opioid treatment (all participants received different duration taper)
Stitzer 1983 All participants received detoxification, no maintenance comparison
Strain 1996 Participants were primarily using heroin
Strang 2000 Participants were primarily using heroin
Tennant 1982 Study design was not a randomised controlled trial
Uehlinger 1998 Unable to confirm if any participants were dependent on pharmaceutical opioids
Weiss 2011 All participants received buprenorphine (no non-buprenorphine control group). Participants were randomised
to receive enhanced counselling versus standard care
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D A T A A N D A N A L Y S E S
Comparison 1. Full opioid agonists versus different full opioid agonists or partial opioid agonists




participants Statistical method Effect size
1 Days of unsanctioned opioid use 1 129 Mean Difference (IV, Random, 95% CI) -1.41 [-3.37, 0.55]
2 Opioid positive urine drug
screen at treatment completion
2 196 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.56, 1.18]
3 Self reported substance use (end
of treatment)
2 155 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.08, 1.63]
4 Retention 3 360 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.39, 1.22]
5 Pain 2 153 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.22, 0.43]
6 Risk behaviours 1 170 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.02, 12.64]
7 Adverse effects 2 196 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.64, 1.91]
8 Physical health 1 127 Mean Difference (IV, Random, 95% CI) 1.28 [-3.83, 6.39]
9 Psychological health 1 127 Mean Difference (IV, Random, 95% CI) -2.13 [-10.06, 5.80]
Comparison 2. Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological
treatment




participants Statistical method Effect size
1 Days of unsanctioned opioid use 2 133 Std. Mean Difference (IV, Random, 95% CI) -0.31 [-0.66, 0.04]
2 Opioid positive (per urine drug
screen, last week of treatment
maintenance)
3 206 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.43, 0.91]
3 Self reported opioid use at
treatment completion (past 30
days)
3 204 Risk Ratio (IV, Random, 95% CI) 0.54 [0.31, 0.93]
4 Retention 3 247 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.23, 0.47]
5 Pain (some to extreme pain or
discomfort)
1 36 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.27, 1.01]
6 Risk behaviours 2 117 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.04, 3.67]
7 Adverse events 2 166 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.06, 0.57]
8 Physical health 1 36 Mean Difference (IV, Random, 95% CI) 31.08 [12.40, 49.76]
9 Psychological health (moderate
to extremely anxious or
depressed)
1 36 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.53, 1.50]
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Analysis 1.1. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 1 Days of unsanctioned opioid use.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 1 Days of unsanctioned opioid use





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Saxon 2013 53 1.51 (4.972) 76 2.92 (6.381) 100.0 % -1.41 [ -3.37, 0.55 ]
Total (95% CI) 53 76 100.0 % -1.41 [ -3.37, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 2 Opioid positive urine drug screen at treatment completion.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 2 Opioid positive urine drug screen at treatment completion








Neumann 2013 2/13 5/13 6.5 % 0.40 [ 0.09, 1.70 ]
Saxon 2013 25/66 46/104 93.5 % 0.86 [ 0.59, 1.25 ]
Total (95% CI) 79 117 100.0 % 0.81 [ 0.56, 1.18 ]
Total events: 27 (Methadone), 51 (Buprenorphine)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 3 Self reported substance use (end of treatment).
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 3 Self reported substance use (end of treatment)








Neumann 2013 0/13 5/13 21.4 % 0.09 [ 0.01, 1.49 ]
Saxon 2013 11/53 29/76 78.6 % 0.54 [ 0.30, 0.99 ]
Total (95% CI) 66 89 100.0 % 0.37 [ 0.08, 1.63 ]
Total events: 11 (Methadone), 34 (Buprenorphine)
Heterogeneity: Tau2 = 0.63; Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 4 Retention.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 4 Retention














Ahmadi 2003 57/68 40/68 31.1 % 0.39 [ 0.21, 0.72 ]
Neumann 2013 13/28 13/26 34.7 % 1.07 [ 0.64, 1.80 ]
Saxon 2013 51/66 72/104 34.2 % 0.74 [ 0.43, 1.26 ]
Total (95% CI) 162 198 100.0 % 0.69 [ 0.39, 1.22 ]
Total events: 121 (Methadone), 125 (Buprenorphine)
Heterogeneity: Tau2 = 0.17; Chi2 = 6.32, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 5 Pain.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 5 Pain







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Neumann 2013 13 88.6 (24.5) 13 87.4 (33.4) 17.6 % 0.04 [ -0.73, 0.81 ]
Saxon 2013 51 67.39 (26.535) 76 64.22 (26.464) 82.4 % 0.12 [ -0.24, 0.47 ]
Total (95% CI) 64 89 100.0 % 0.11 [ -0.22, 0.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 6 Risk behaviours.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 6 Risk behaviours








Saxon 2013 0/66 1/104 100.0 % 0.52 [ 0.02, 12.64 ]
Total (95% CI) 66 104 100.0 % 0.52 [ 0.02, 12.64 ]
Total events: 0 (Methadone), 1 (Buprenorphine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 7 Adverse effects.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 7 Adverse effects








Neumann 2013 9/13 8/13 94.7 % 1.13 [ 0.64, 1.97 ]
Saxon 2013 1/66 2/104 5.3 % 0.79 [ 0.07, 8.52 ]
Total (95% CI) 79 117 100.0 % 1.10 [ 0.64, 1.91 ]
Total events: 10 (Methadone), 10 (Buprenorphine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 8 Physical health.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 8 Physical health





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Saxon 2013 51 56.67 (13.904) 76 55.39 (15.134) 100.0 % 1.28 [ -3.83, 6.39 ]
Total (95% CI) 51 76 100.0 % 1.28 [ -3.83, 6.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Full opioid agonists versus different full opioid agonists or partial opioid
agonists, Outcome 9 Psychological health.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 1 Full opioid agonists versus different full opioid agonists or partial opioid agonists
Outcome: 9 Psychological health





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Saxon 2013 51 60.71 (21.38) 76 62.84 (23.703) 100.0 % -2.13 [ -10.06, 5.80 ]
Total (95% CI) 51 76 100.0 % -2.13 [ -10.06, 5.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 1 Days of unsanctioned opioid use.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 1 Days of unsanctioned opioid use







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
D’Onofrio 2015 26 0.5 (1.2379) 38 1.25 (2.1982) 48.5 % -0.40 [ -0.90, 0.11 ]
Fiellin 2014 43 2.05 (4.84) 26 3.32 (6.34) 51.5 % -0.23 [ -0.72, 0.26 ]
Total (95% CI) 69 64 100.0 % -0.31 [ -0.66, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.083)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 2 Opioid positive (per urine drug screen, last week of treatment
maintenance).
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 2 Opioid positive (per urine drug screen, last week of treatment maintenance)








D’Onofrio 2015 5/22 10/34 14.3 % 0.77 [ 0.30, 1.96 ]
Fiellin 2014 31/56 47/57 75.4 % 0.67 [ 0.52, 0.87 ]
Woody 2008 3/19 10/18 10.3 % 0.28 [ 0.09, 0.87 ]
Total (95% CI) 97 109 100.0 % 0.63 [ 0.43, 0.91 ]
Total events: 39 (BPN maintenance), 67 (Taper/TAU)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.42, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 3 Self reported opioid use at treatment completion (past 30 days).
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 3 Self reported opioid use at treatment completion (past 30 days)
Study or subgroup BPN maintenance Taper/TAU Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
D’Onofrio 2015 6/26 12/38 25.1 % 0.73 [ 0.31, 1.70 ]
Fiellin 2014 27/56 42/57 51.5 % 0.65 [ 0.48, 0.89 ]
Woody 2008 4/18 8/9 23.4 % 0.25 [ 0.10, 0.61 ]
Total (95% CI) 100 104 100.0 % 0.54 [ 0.31, 0.93 ]
Total events: 37 (BPN maintenance), 62 (Taper/TAU)
Heterogeneity: Tau2 = 0.13; Chi2 = 4.18, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 4 Retention.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 4 Retention














D’Onofrio 2015 23/27 24/54 14.4 % 0.27 [ 0.10, 0.68 ]
Fiellin 2014 37/56 6/57 71.0 % 0.38 [ 0.26, 0.55 ]
Woody 2008 23/27 6/26 14.6 % 0.19 [ 0.08, 0.49 ]
Total (95% CI) 110 137 100.0 % 0.33 [ 0.23, 0.47 ]
Total events: 83 (BPN maintanence), 36 (Taper/TAU)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.17, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 6.03 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 5 Pain (some to extreme pain or discomfort).
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 5 Pain (some to extreme pain or discomfort)








Woody 2008 7/19 12/17 100.0 % 0.52 [ 0.27, 1.01 ]
Total (95% CI) 19 17 100.0 % 0.52 [ 0.27, 1.01 ]
Total events: 7 (BPN maintenance), 12 (Taper/TAU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 6 Risk behaviours.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 6 Risk behaviours








D’Onofrio 2015 0/26 1/38 49.9 % 0.48 [ 0.02, 11.38 ]
Woody 2008 0/27 1/26 50.1 % 0.32 [ 0.01, 7.55 ]
Total (95% CI) 53 64 100.0 % 0.39 [ 0.04, 3.67 ]
Total events: 0 (BPN maintenance), 2 (Taper/TAU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours BPN maintenance Favours taper/TAU
52Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.7. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 7 Adverse events.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 7 Adverse events








Fiellin 2014 3/56 16/57 86.6 % 0.19 [ 0.06, 0.62 ]
Woody 2008 0/27 2/26 13.4 % 0.19 [ 0.01, 3.84 ]
Total (95% CI) 83 83 100.0 % 0.19 [ 0.06, 0.57 ]
Total events: 3 (BPN maintenance), 18 (Taper/TAU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.96 (P = 0.0031)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 8 Physical health.
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 8 Physical health





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Woody 2008 19 82.37 (23.78) 17 51.29 (32.23) 100.0 % 31.08 [ 12.40, 49.76 ]
Total (95% CI) 19 17 100.0 % 31.08 [ 12.40, 49.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Full or partial opioid agonist maintenance versus placebo, detoxification only,
or psychological treatment, Outcome 9 Psychological health (moderate to extremely anxious or depressed).
Review: Opioid agonist treatment for pharmaceutical opioid dependent people
Comparison: 2 Full or partial opioid agonist maintenance versus placebo, detoxification only, or psychological treatment
Outcome: 9 Psychological health (moderate to extremely anxious or depressed)








Woody 2008 11/19 11/17 100.0 % 0.89 [ 0.53, 1.50 ]
Total (95% CI) 19 17 100.0 % 0.89 [ 0.53, 1.50 ]
Total events: 11 (BPN maintenance), 11 (Taper/TAU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search strategies 2015
Cochrane Drugs and Alcohol Group (CDAG) Specialised Register of Trials
1 (((prescript* OR prescrib* OR pharmaceutical) NEAR (opioid* OR opiate*))) AND (INREGISTER)
2 (((opiate* OR opioid* OR morphin* OR morfin* OR narcot*) NEAR (abuse* OR abusing OR addict* OR misus* OR depend*
OR disorder*)):TI:AB) AND (INREGISTER)
3 ((opiate* OR opioid*):XDI) AND (INREGISTER)
4 #2 AND #3
5 #1 AND #4
6 ((prescript* OR prescrib* OR pharmaceutical):XDI) AND (INREGISTER)
7 #5 OR #6
Cochrane Central Register of Controlled Trials (CENTRAL)
1. MESH DESCRIPTOR Opioid-Related Disorders EXPLODE ALL TREES
2. (((opiate* OR opioid* OR morphin* OR morfin* OR narcot*) NEAR (abuse* OR abusing OR addict* OR misus* OR depend*
OR disorder*))):TI,AB,KY
3. #1 OR #2
4. (((opioid* OR opiat*) NEAR analges*)):TI,AB,KY
5. ((prescript* OR prescrib* OR pharmaceutical) NEAR (opioid* OR opiate*)):TI,AB,KY
6. MESH DESCRIPTOR Prescription Drugs EXPLODE ALL TREES
7. MESH DESCRIPTOR Narcotics
8. MESH DESCRIPTOR Analgesics, Opioid EXPLODE ALL TREES
9. #4 OR #5 OR #6 OR #7 OR
10. #3 AND #9
PubMed
1. “Opioid-Related Disorders”[MeSH]
2. ((opiate*[tiab] OR opioid*[tiab] OR morphin*[tiab] OR morfin*[tiab] OR narcot*[tiab]) AND (abuse*[tiab] OR abusing[tiab]
OR addict*[tiab] OR misus*[tiab] OR depend*[tiab] OR disorder*[tiab]))
3. #1 OR #2
4. “Analgesics, Opioid”[MeSH]
5. “Narcotics”[MeSH]
6. ((opioid*[tiab] OR opiat*[tiab]) AND analges*[tiab])
7. “Prescription Drugs”[MeSH]
8. ((prescript*[tiab] OR prescrib*[tiab] OR pharmaceutical[tiab]) AND (opioid*[tiab] OR opiate*[tiab]))
9. #4 OR #5 OR #6 OR #7 OR #8
10. randomized controlled trial [pt]
11. controlled clinical trial [pt]
12. randomized [tiab]
13. placebo [tiab]




18. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
19. animals [mh] NOT humans [mh]
20. #18 NOT #19
21. #3 AND #9 AND #20
EMBASE
opiate addiction’/exp OR ((opiate* OR opioid* OR morphin* OR morfin* OR narcot*) NEAR/3 (abuse* OR abusing OR addict* OR
misus* OR depend* OR disorder*)):ab,ti AND (’narcotic analgesic agent’/exp OR ’narcotic agent’/exp OR (analges* NEAR/6 (opioid*
OR opiat*)):ab,ti OR ’prescription drug’/exp OR ((prescript* OR prescrib* OR pharmaceutical) NEAR/6 (opioid* OR opiate*)):ab,ti)
AND (’crossover procedure’/exp OR ’double blind procedure’/exp OR ’single blind procedure’/exp OR ’controlled clinical trial’ OR
55Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
’clinical trial’/exp OR placebo:ab,ti OR ’double blind’:ab,ti OR ’single blind’:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:
ab,ti OR random*:ab,ti OR factorial*:ab,ti OR crossover:ab,ti OR (cross:ab,ti AND over:ab,ti) OR ’randomized controlled trial’/exp)
CINAHL
S19 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18
S18 TI placebo* or AB placebo*
S17 TI random* allocat* or AB random* allocat*
S16 MH “Random Assignment”
S15 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S14 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S13 TI clinic* N1 trial* or AB clinic* N1 trial*
S12 PT Clinical trial
S11 MH “Clinical Trials+”
S10 S3 AND S9
S9 S4 OR S5 OR S6 OR S7 OR S8
S8 TX (prescript* or prescrib* or pharmaceutical) N6 (opioid* or opiate*)
S7 (MH “Drugs, Prescription”)
S6 TX (analges* N6 (opioid* or opiate*))
S5 MH “Analgesics, Opioid+”
S4 (MH “Narcotics+”)
S3 S1 OR S2
S2 TX (opiate* or opioid* or morphin* or morfin* or narcot*) N6 (abuse* or abusing or addict* or misus* or depend* or disorder*)
S1 (MH “Substance Use Disorders+”)
ISI Web of Science
7. #6 AND #2 AND #1
6. #5 OR #4 OR #3
5. TOPIC: (“prescription drugs”)
4. TS=((prescript* or prescrib* or pharmaceutical) NEAR/3 (opioid* or opiate*))
3. TS=((opioid* or opiat*) near/2 analges*)
2. TS=(((opiate* or opioid* or morphin* or morfin* or narcot*) NEAR/6 (abuse* or abusing or addict* or misus* or depend*)))
1. TS= clinical trial* OR TS=research design OR TS=comparative stud* OR TS=evaluation stud* OR TS=controlled trial* OR TS=
follow-up stud* OR TS=prospective stud* OR TS=random* OR TS=placebo* OR TS=(single blind*) OR TS=(double blind*)
PsycINFO
1. exp Drug Dependency/ or exp Drug Abuse/ or exp Drug Withdrawal/ or exp Drug Addiction/
2. addiction/
3.((narcotic$ or opiate$ or opioid$ or morphin$) adj3 (misuse or abuse$ or addict$ or depend$)).ti,ab.
4. 1 or 2 or 3
5. ((opioid* or opiat*) adj3 analges*).ti,ab.
6. narcotic agonists/ or narcotic drugs/ or apomorphine/ or meperidine/ or methadone/ or tramadol/ or analgesic drugs/
7. exp Morphine/ or exp Analgesia/ or exp Analgesic Drugs/
8. prescription drugs/
9. ((prescript* or prescrib* or pharmaceutical) adj3 (opioid* or opiate*)).ti,ab.
10. or/5-9
11. 4 and 10
12. animals/ not (animals/ and human$.mp.)
13. (animal/ or animals/) not ((animal/ and human/) or (animals/ and humans/))





19. exp Clinical Trials/
20. or/15-19
21. 20 not (12 or 13 or 14)
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22. 11 and 21
Appendix 2. Criteria for risk of bias assessment
Item Judgement Description
Random sequence generation (selection
bias)
Low risk The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimisation
High risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability of
the intervention
Unclear risk Insufficient information about the sequence generation process to permit
judgement of low or high risk
Allocation concealment (selection bias) Low risk Investigators enrolling participants could not foresee assignment because
one of the following, or an equivalent method, was used to conceal al-
location: central allocation (including telephone, web-based, and phar-
macy-controlled randomisation); sequentially numbered drug contain-
ers of identical appearance; sequentially numbered, opaque, sealed en-
velopes
High risk Investigators enrolling participants could possibly foresee assignments
because one of the following methods was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or
not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure
Unclear risk Insufficient information to permit judgement of low or high risk. This
is usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgement
Blinding of participants and providers (per-
formance bias)
Objective outcomes
Low risk No blinding or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding
Blinding of participants and key study personnel ensured, and unlikely
that the blinding could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding; or
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
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(Continued)
Unclear risk Insufficient information to permit judgement of low or high risk
Blinding of participants and providers (per-
formance bias)
Subjective outcomes
Low risk Blinding of participants and providers and unlikely that the blinding
could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
Blinding of outcome assessor (detection
bias)
Objective outcomes
Low risk No blinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
Blinding of outcome assessor (detection
bias)
Subjective outcomes
Low risk No blinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
Incomplete outcome data (attrition bias)
For all outcomes except retention
Low risk No missing outcome data
Reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias)
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk not enough to have a clinically relevant
impact on the intervention effect estimate
For continuous outcome data, plausible effect size (difference in means or
standardised difference in means) among missing outcomes not enough
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to have a clinically relevant impact on observed effect size
Missing data have been imputed using appropriate methods
All randomised participants are reported/analysed in the group they were
allocated to by randomisation irrespective of non-compliance and co-
interventions (intention to treat)
High risk Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across
intervention groups
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant
bias in intervention effect estimate
For continuous outcome data, plausible effect size (difference in means
or standardised difference in means) among missing outcomes enough
to induce clinically relevant bias in observed effect size
’As-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomisation
Unclear risk Insufficient information to permit judgement of low or high risk (e.g.
number randomised not stated, no reasons for missing data provided;
number of drop-out not reported for each group)
Selective reporting (reporting bias) Low risk The study protocol is available and all of the study’s pre-specified (primary
and secondary) outcomes that are of interest in the review have been
reported in the pre-specified way
The study protocol is not available but it is clear that the published reports
include all expected outcomes, including those that were pre-specified
(convincing text of this nature may be uncommon)
High risk Not all of the study’s pre-specified primary outcomes have been reported
One or more primary outcomes is reported using measurements, analysis
methods, or subsets of the data (e.g. subscales) that were not pre-specified
One or more reported primary outcomes were not pre-specified (unless
clear justification for their reporting is provided, such as an unexpected
adverse effect)
One or more outcomes of interest in the review are reported incompletely
so that they cannot be entered in a meta-analysis
The study report fails to include results for a key outcome that would be
expected to have been reported for such a study
Unclear risk Insufficient information to permit judgement of low or high risk
59Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
Draft the protocol SN, LD, NL, LG
Develop and run the search strategy SN, BL, LD, CK
Obtain copies of studies CK, BL, SN
Select which studies to include (2 people) SN, BL
Extract data from studies (2 people) SN, BL
Enter data into RevMan SN
Carry out the analysis SN
Interpret the analysis SN, LD, NL, LG
Draft the final review SN, LD, NL, LG
Update the review SN, BL, LD, NL, LG
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We had originally intended to include any studies with pharmaceutical opioid dependent people in analyses if they could provide data
for only those participants that were dependent on pharmaceutical opioids. On contacting authors, we became aware that some studies
had only recruited very small numbers (e.g. two or three participants) of people who were dependent on pharmaceutical opioids,
preventing meaningful analyses. For this reason, we added the criteria that at least 10 people must have been recruited who were
dependent on pharmaceutical opioids to warrant re-analyses of the data for those people.
We did not produce funnel plots to examine risk of bias because of the small number of studies identified.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Prescription Drug Misuse; Analgesics, Opioid [therapeutic use]; Buprenorphine [∗therapeutic use]; Methadone [∗therapeutic use];
Narcotics [∗therapeutic use]; Opiate Substitution Treatment [∗methods]; Opioid-Related Disorders [∗drug therapy]; Randomized
Controlled Trials as Topic
MeSH check words
Humans
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